Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00556920 · ClinicalTrials.gov registry record · Phase 1

Study to Demonstrate the Bioequivalence of the Fixed Dose Combination of COREG CR™ and Lisinopril to Its Components

A Phase 1 study of Hypertension, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 1
Development phase
50
Enrollment target
1
Study location

NCT00556920 is a Phase 1 study of Hypertension that has completed, run by GlaxoSmithKline. The registered enrollment target is 50 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00556920, a Phase 1 study of Hypertension, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 1
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This study will be a randomized study investigating the bioequivalence of COREG CR and Lisinopril to COREG CR and ZESTRIL

Conditions Studied

Hypertension

Interventions

  • DRUG COREG CR

Study Locations (1)

New York

  • GSK Investigational Site - Buffalo

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2007-10
Est. Completion 2007-12
Phase Phase 1

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00556920

The ClinicalTrials.gov registry entry for NCT00556920 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which COREG CR is the first listed.

NCT00556920 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00556920 about?

NCT00556920 is a clinical study titled "Study to Demonstrate the Bioequivalence of the Fixed Dose Combination of COREG CR™ and Lisinopril to Its Components". This study will be a randomized study investigating the bioequivalence of COREG CR and Lisinopril to COREG CR and ZESTRIL

What is the current status of trial NCT00556920?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2007-10. Estimated completion is 2007-12.

What conditions does trial NCT00556920 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT00556920?

The interventions under investigation include: COREG CR (DRUG).

Who is sponsoring clinical trial NCT00556920?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00556920 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypertension

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.